Chen, Michelle H.
Goverover, Yael
Genova, Helen M.
DeLuca, John
Funding for this research was provided by:
National MS Society (MB-1606-08779, CA1069-A-7)
Article History
First Online: 2 May 2020
Compliance with Ethical Standards
:
: The preparation of this manuscript was supported in part by National Multiple Sclerosis Society Grant MB-1606-08779 to John DeLuca, NMSS Grant CA1069-A-7 to John DeLuca, and the Kessler Foundation. Open access publishing was paid for by Kessler Foundation.
: Helen M. Genova has received funding from the National Multiple Sclerosis Society. John DeLuca has received funding from the National Multiple Sclerosis Society; served as a consultant or member of the advisory board for Biogen, Celgene, Novartis, and MedRhythms; provided paid lectures for Biogen and Sanofi-Genzyme; and received book loyalties. Michelle H. Chen and Yael Goverover declare no potential conflicts of interest.